Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Clinical Diabetes
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1502050
This article is part of the Research Topic Digital Technology in the Management and Prevention of Diabetes: Volume II View all 3 articles

Risk factors screening and prediction modeling of gastrointestinal adverse reactions caused by GLP-1RAs

Provisionally accepted
Rui Gao Rui Gao 1Yue Li Yue Li 1,2Anan Li Anan Li 3Penglin Zhou Penglin Zhou 3Huiying Zong Huiying Zong 3Yan LI Yan LI 1*
  • 1 The First Affiliated Hospital of Shandong First Medical University, Jinan, China
  • 2 Qilu Institute of Technology (QIT), Jinan, Shandong Province, China
  • 3 Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China

The final, formatted version of the article will be published soon.

    Objective: To explore the risk factors for gastrointestinal side effects (GISEs) in patients with type 2 diabetes mellitus (T2DM) during treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) based on real-world data, and to develop a prediction model for GLP-1RAs related GISEs. Methods: A total of 855 patients who attended the First Affiliated Hospital of Shandong First Medical University from January 2020 to May 2023 were selected as the study participants, and were divided into the training set (598 cases) and validation set (297 cases) by using simple random sampling method in a ratio of 7:3. General information and biochemical indicators of participants were collected to assess the risk factors for GLP-1RAs related GISEs, and multifactorial logistic regression analysis was used to obtain the best predictors. The nomogram prediction model was constructed, Hosmer-Lemeshow test was used to assess the differentiation and calibration of the nomogram model, and decision curve analysis (DCA) was used to evaluate the clinical utility of the model. Results: Age, gender, history of gastrointestinal disorders, and number of combined oral medications were the risk factors for the occurrence of GISEs in T2DM patients using GLP-1RAs (P < 0.05). The nomogram prediction model based on the four factors had a good discriminability (AUC values of the training set and validation set were 0.855 and 0.836, respectively) and accuracy (Hosmer-Lemeshow test: P > 0.05 for the validation set). DCA curve analysis showed that the prediction model curve had clinical utility in the threshold probability interval of > 5 %. Conclusions: The established nomogram model has an excellent predictive effect on GISEs induced by GLP-1RAs in T2DM patients.

    Keywords: type 2 diabetes mellitus, glucagon-like peptide-1 receptor agonists, Gastrointestinal side effects, Risk factors, nomogram

    Received: 26 Sep 2024; Accepted: 11 Nov 2024.

    Copyright: © 2024 Gao, Li, Li, Zhou, Zong and LI. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yan LI, The First Affiliated Hospital of Shandong First Medical University, Jinan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.